(2S,3R,4R,5S)-2-(4-Chloro-3-(4-(2-hydroxyethoxy)benzyl)phenyl)-6-methoxytetrahydro-2Hpyran-3,4,5-triol

ID: ALA567743

Chembl Id: CHEMBL567743

PubChem CID: 44480436

Max Phase: Preclinical

Molecular Formula: C21H25ClO7

Molecular Weight: 424.88

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COC1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCO)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C21H25ClO7/c1-27-21-19(26)17(24)18(25)20(29-21)13-4-7-16(22)14(11-13)10-12-2-5-15(6-3-12)28-9-8-23/h2-7,11,17-21,23-26H,8-10H2,1H3/t17-,18-,19+,20+,21?/m1/s1

Standard InChI Key:  CHFZDLOZVXBPTO-AUGMSIGLSA-N

Associated Targets(Human)

SLC5A2 Tclin Sodium/glucose cotransporter 2 (2000 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Slc5a2 Sodium/glucose cotransporter 2 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 424.88Molecular Weight (Monoisotopic): 424.1289AlogP: 1.43#Rotatable Bonds: 7
Polar Surface Area: 108.61Molecular Species: NEUTRALHBA: 7HBD: 4
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 12.20CX Basic pKa: CX LogP: 1.97CX LogD: 1.97
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.53Np Likeness Score: 0.76

References

1. Goodwin NC, Mabon R, Harrison BA, Shadoan MK, Almstead ZY, Xie Y, Healy J, Buhring LM, DaCosta CM, Bardenhagen J, Mseeh F, Liu Q, Nouraldeen A, Wilson AG, Kimball SD, Powell DR, Rawlins DB..  (2009)  Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,  52  (20): [PMID:19785435] [10.1021/jm900951n]

Source